We investigated the frequency and mode of relapses of acute leukemia after allogeneic BMT in a series of 50 consecutive patients. The median age of patients was 31.5 years with 26 males. Thirty-two patients had AML. Forty-three patients were in first CR. All patients received BuCy regimen with GVHD prophylaxis of cyclosporine plus methotrexate. After a median followup time of 22.4 months (range, 6.0-52.9), 14 patients (28%) relapsed. Seven patients (50%) relapsed in the bone marrow only; three (21%) relapsed in extramedullary sites only; and four (29%) relapsed in both extramedullary sites and bone marrow. Times to relapses in bone marrow only (median 6.3 months) were significantly shorter when compared to times to extramedullary relapses with or without bone marrow involvement (median 12.3 months, P = 0.048). Sites of extramedullary relapses varied widely among the patients. In conclusion, we observed a high frequency of extramedullary relapses of acute leukemia after allogeneic BMT (50%). The GVL effect observed in the extramedullary sites of the body may not be as effective as in the bone marrow in patients with acute leukemia after allogeneic BMT. Bone Marrow Transplantation (2000) 26, 147-152. Keywords: extramedullary relapse; acute leukemia; allogeneic BMT; GVL effect Twenty to 50% of patients with acute leukemia relapse with their disease after allogeneic bone marrow transplantation (BMT). Factors that predict relapse of leukemia after allogeneic BMT are status of disease at the time of BMT, T cell-depleted marrow transplantation, and absence of graftversus-host disease (GVHD). [1] [2] [3] [4] It is now well known that relapse of acute leukemia is less frequent after allogeneic BMT than after autologous or syngeneic BMT and this is attributed to the graft-versus-leukemia (GVL) effect that occurs after allogeneic BMT. [5] [6] [7] In a series of 50 consecutive patients with acute leukemia who underwent allogeneic BMT in our hospital, we observed an unusually high frequency of extramedullary relapse. Overall, frequency of relapses (both medullary and
Twenty to 50% of patients with acute leukemia relapse with their disease after allogeneic bone marrow transplantation (BMT). Factors that predict relapse of leukemia after allogeneic BMT are status of disease at the time of BMT, T cell-depleted marrow transplantation, and absence of graftversus-host disease (GVHD). [1] [2] [3] [4] It is now well known that relapse of acute leukemia is less frequent after allogeneic BMT than after autologous or syngeneic BMT and this is attributed to the graft-versus-leukemia (GVL) effect that occurs after allogeneic BMT. [5] [6] [7] In a series of 50 consecutive patients with acute leukemia who underwent allogeneic BMT in our hospital, we observed an unusually high frequency of extramedullary relapse. Overall, frequency of relapses (both medullary and extramedullary) was similar to the historically observed relapse rate of acute leukemia after allogeneic BMT. We hypothesized that the GVL effect observed after allogeneic BMT in extramedullary sites of the body may not be as potent as in the medullary site in patients with acute leukemia. In addition, the GVL effect may not be uniformly effective throughout the body in patients with acute leukemia.
Patients and methods

Transplantation procedures
Detailed transplantation procedures were described elsewhere. 8, 9 All patients received the BuCy regimen (busulfan 4 mg/kg/day on days −7 to −4 and cyclophosphamide 60 mg/kg/day on days −3 to −2) for preparation for BMT. Regimens for prophylaxis of GVHD included cyclosporine 1.5 mg/kg intravenously every 12 h starting on day −1, then switched to an oral dose 4 times the intravenous dose when oral intake became feasible. Methotrexate 15 mg/m 2 was given intravenously on day 1, then 10 mg/m 2 was given on days 3, 6 and 11. Methotrexate was not given if there was grade III or higher oral mucositis. If there was no evidence of GVHD, cyclosporine dose was tapered by 10% each month starting on day 60.
Methotrexate 10 mg/m 2 (not to exceed 12 mg) was administered intrathecally along with oral leucovorin 15 mg 4 h later, every 6 h for eight doses before initiation of the preparative regimen. After hematologic recovery of patients after BMT, intrathecal methotrexate was repeated every 2 weeks three times, along with the same doses of oral leucovorin.
Diphenylhydantoin was administered during busulfan administration. Mesna was administered during cyclophosphamide administration along with intravenous hydration. Granulocyte colony-stimulating factor (G-CSF) 450 g was administered intravenously daily starting on either day 1 or 5 of BMT until the peripheral blood absolute neutrophil count (ANC) was over 3000/l. 9 
Monitoring of patients
Blood was drawn everyday for complete blood count and reticulocyte count. Blood chemistry, electrolytes including magnesium, and blood coagulation were assessed once or twice weekly, or more frequently as necessary. All patients were monitored prospectively for the occurrence of adverse events, including GVHD, veno-occlusive disease of the liver (VOD), and infections. Acute and chronic GVHD was classified according to the criteria of Thomas et al 10 and Sullivan et al, 11 respectively. A diagnosis of VOD was made according to the clinical criteria of McDonald et al 12 as two of the following occurring before day 20 of BMT: (1) hyperbilirubinemia (bilirubin у2.0 mg/dl or 34.2 mol/l), (2) painful hepatomegaly, and (3) unexplained weight gain (Ͼ2% from baseline), no other explanation for these signs and symptoms being present at the time of diagnosis. The severity of VOD was classified as mild, moderate, or severe. 13 
Criteria for bone marrow engraftment
The first days of ANC equal or over 500/l and 1000/l for 2 consecutive days were recorded for neutrophil engraftment. The first day of an unsupported platelet count equal to or over 20 000/l for 7 consecutive days was recorded. When patients were independent of red blood cell (RBC) transfusion for over a month, the last day of RBC transfusion was recorded as a day of RBC transfusion independence.
Statistical analysis
Variables were compared using the chi-square test. Continuous variables were compared using Mann-Whitney test. Time to relapse, and survival curves were plotted by the Kaplan-Meier method.
Results
Patient characteristics
Between March 1995 and December 1998, 50 patients with acute leukemia underwent allogeneic BMT. Patient and transplant characteristics are shown in Table 1 . Median age of patients was 31.5 years (range, 17-47). There were 26 males and 24 females. One patient had extramedullary disease at the time of diagnois of acute leukemia (leptomeninges). Forty-three patients were in their first CR at the time of BMT.
Engraftment and post-transplant clinical course
Forty-nine of 50 patients achieved an ANC over 500/l for at least 2 consecutive days at a median of 15.5 days after BMT. Forty-five patients achieved an unsupported platelet count of 20 000/l for 7 consecutive days at a median of 27 days. Forty-four patients achieved RBC transfusion independence at a median of 20.5 days. Four patients (8%) experienced acute GVHD (grades I and II in one patient each; grade III in two patients, Table 2 ). Fifteen patients (30%) experienced chronic GVHD (limited in 12 patients; extensive in three patients, Table 2 ). Moderate to severe VOD occurred in 19 patients (38%). Six patients died within 100 days of BMT due to regimen-related toxicities (three patients with VOD/multiorgan failure; one with sep- sis; one with graft failure, one with CNS bleeding). Two patients died 5.1 and 11.0 months after BMT without evidence of leukemia due to CMV pneumonia and fulminant hepatitis B, respectively.
Relapse of acute leukemia
Median follow-up time of patients who were alive at the time of the analysis was 22.4 months (range, 6.0-52.9 months). Fourteen patients (28%) experienced leukemia relapse (Table 3) . None of the patients who relapsed had extramedullary disease at the time of diagnosis of their acute leukemia. Seven patients (50%) relapsed in the bone marrow only at a median of 6.3 months (range 5.5-12.9 months) after BMT. Three (21%) relapsed in extramedullary sites only at 5.0, 26.9 and 34.4 months after BMT. Four (29%) relapsed in both extramedullary sites and the bone marrow at 11.8, 12.3, 17.0 and 34.4 months after BMT. When times from BMT to the initial relapses were compared according to the mode of relapse, times to relapse in bone marrow only were significantly shorter when com- pared to times to extramedullay relapse with or without bone marrow involvement (median 17.0 months, range 5.0-34.4 months, P = 0.048, Figure 1 ). Three patients experienced multiple episodes of leukemia relapse (UPNs 17, 60 and 62, Table 2 shows the relationship between mode of initial leukemia relapse and clinical characteristics of patients. No characteristic was associated with a particular mode of leukemia relapse. None of the four patients who experienced acute GVHD after BMT relapsed. Among 15 patients who experienced chronic GVHD, three relapsed in extramedullary sites with or without bone marrow involvement. No patients who experienced chronic GVHD relapsed with marrow disease only.
Response to treatment after relapse
Twelve patients with relapsed acute leukemia in the bone marrow with or without extramedullary site involvement were treated with chemotherapy and received donor leukocytes. Patients with extramedullary involvement in addition to bone marrow involvement received local radiation therapy to involved sites when bone marrow recovery was evident (Table 3) . Ten patients (83%) achieved CR. All patients who achieved CR experienced GVHD. Of 10
Bone Marrow Transplantation patients who achieved CR, six are free of leukemia at 1.6-23.3 months after salvage treatment.
Overall survival of patients
Fourteen patients (28%) died at a median of 7.3 months (range, 0.9-27.7) after BMT. A Kaplan-Meier survival curve is depicted in Figure 2 .
Discussion
In our series of 50 patients who underwent allogeneic BMT for acute leukemia, 50% of first episodes of leukemia relapse (7/14) and 53% of all episodes of leukemia relapses (10/19) were extramedullary, with or without bone marrow involvement. Our finding is consistent with the data of Simpson et al 14 who reported a similar frequency of extramedullary relapse (45% of all relapses) with or without bone marrow involvement among 81 patients with AML. In both studies, patients received the BuCy regimen for preparation for BMT. Extramedullary relapses occurred later than relapses in the bone marrow only and the distribution of extramedullary sites of relapse varied widely among patients in both studies.
At present, it is not certain why there are apparently excessive extramedullary relapses of acute leukemia after allogeneic BMT. One randomized study reported a higher incidence of relapse of AML among patients who received the BuCy regimen as opposed to cyclophosphamide plus total body irradiation (Cy-TBI) regimen, 15 while another study failed to show such a difference. 16 The mode of leukemia relapse was not stated in either study. Inter-patient variation in busulfan absorption and metabolism may result in low plasma levels of the drug and poor tissue penetration in a proportion of patients and may explain the apparent high incidence of extramedullary relapse. 17, 18 However, it does not explain adequately the delay in occurrence of extramedullary relapses as opposed to bone marrow relapses after BMT. Late extramedullary relapses of acute leukemia have also been reported after allogeneic BMT prepared with TBI containing regimens. [19] [20] [21] [22] [23] It is now well established that GVL effect plays a significant role in the prevention of relapse of leukemia after allogeneic BMT. [24] [25] [26] In our study, overall frequency of relapse of acute leukemia is 28% which is comparable to the historically observed relapse rate after allogeneic BMT. In view of the apparently higher relative frequency of extramedullay relapse of acute leukemia after allogeneic BMT, we may hypothesize that the GVL effect observed after BMT in extramedullary sites of the body of patients with acute leukemia may not be as effective as in the bone marrow. It may be that those patients with leukemic cells that are resistant to the GVL effect of allogeneic BMT may develop recurrence soon after BMT in the marrow where the leukemia burden is heaviest. When leukemic cells are sensitive to the GVL effect, they may be suppressed in the bone marrow by the GVL effect but may escape the GVL effect in the extramedullary sites where the GVL effect may be less uniformly effective. The delay in extramedullary relapse as opposed to bone marrow relapse after allogeneic BMT is consistent with the above hypothesis. The wide distribution of extramedullary sites of relapses among patients suggests uneven effectiveness of the GVL effect throughout the body of patients with acute leukemia after allogeneic BMT. We treated 11 patients with relapsed leukemia in the bone marrow, with or without extramedullary site involvement, with intensive chemotherapy and donor leukocyte infusion. Nine patients achieved CR with concomitant development of GVHD. Two patients (UPNs 60, 62) who subsequently relapsed had disease only in extramedullary sites without bone marrow involvement (Table 4) , which suggested a GVL effect of donor cells suppressing leukemic cells in the bone marrow but not in extramedullary sites. Similar observations have been made by other investigators in acute leukemia as well as in multiple myeloma. 27, 28 Another factor that may contribute to extramedullary relapse of acute leukemia after allogeneic BMT is the property of leukemic cells. Expression of certain cell surface markers such as CD56, CD2, CD4 and CD7, and chromosomal abnormalities [t(8;21), inv (16) ] of leukemic cells are risk factors for extramedullary disease in AML. 29 Further studies are needed to identify risk factors for extramedullary disease in acute leukemia after allogeneic BMT.
Due to the small number of patients in our study, we could not evaluate whether there is any difference in time to relapse between relapses in extramedullary sites only and relapses in both extramedullary sites and the bone marrow. Further studies with larger numbers of patients are warranted.
In conclusion, we observed a high frequency of extramedullary relapse of acute leukemia after allogeneic BMT (50%) although overall frequencies of relapse were comparable to the historically observed relapse rate after allogeneic BMT. We hypothesize that the GVL effect in extramedullary sites of the body may not be as effective as in the marrow in patients with acute leukemia after allogeneic BMT. In addition, the GVL effect may not be uniformly effective throughout the body in patients with acute leukemia. Mode of relapse of acute leukemia
